)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Coherus Oncology (CHRS) investor relations material
Coherus Oncology Biotech Discovery Series summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Biotech Discovery Series summary17 Dec, 2025
Strategic focus and company overview
Transitioned from biosimilars to a fully focused immuno-oncology pipeline, divesting biosimilars and emphasizing innovative cancer therapies.
Toripalimab, an FDA-approved PD-1 inhibitor, serves as the cornerstone of the pipeline, with a management team experienced in end-to-end drug development.
Pipeline includes Casdozokitug (anti-IL-27) and Tagmokitug (CCR8-targeted cytolytic antibody), both aiming to address unmet needs in cancer immunotherapy.
Strategic partnerships and global rights are being pursued, especially for ex-U.S. markets and novel combination therapies.
Casdozokitug (anti-IL-27) clinical development
Demonstrated immune system rebalancing and monotherapy activity in squamous non-small cell lung cancer and renal cell carcinoma.
In HCC, the Casdozo-Atezo-Bev triplet showed a 38% overall response rate and 17% complete response rate, doubling historical CR rates.
Safety profile is favorable, with no significant increase in immune-related adverse events compared to standard regimens.
Ongoing Phase II study substitutes Atezolizumab with Toripalimab, aiming to further characterize efficacy, safety, and dose response.
Initial data from the triplet combo expected mid-2026, with plans for a larger adaptive Phase II/III study to follow.
Tagmokitug (CCR8-targeted antibody) development
Selectively depletes intratumoral Tregs, enhancing anti-tumor immunity without observed off-target toxicity.
Differentiated by high selectivity for CCR8, cytolytic potency via afucosylation, and unique epitope binding.
Early clinical data in head and neck cancer showed Treg depletion and increased CD8 T cells, with promising responses in refractory patients.
Broad development approach includes head and neck, gastric, esophageal, and colorectal cancers, with multiple active protocols.
Data readouts expected in 2026 across several tumor types, including head and neck, gastric, esophageal, and colorectal cancers.
What drives Casdozokitug's 'de facto' HCC potential?
Tagmukitug's competitive edge vs. other CCR8s?
How will 2026 data drive Coherus's long-term growth?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Coherus Oncology earnings date
Q4 202511 Mar, 2026
Next Coherus Oncology earnings date
Q4 202511 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company seeks to create rationally designed molecules for important therapeutic targets that have been the targets of drugs or biological products that are either currently approved or in clinical development for inflammatory, metabolic, autoimmune/lupus, nephrology and cardiovascular/vascular diseases. Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage